Oppenheimer Initiates Coverage of CorMedix at Outperform
Fintel reports that on September 23, 2026, Oppenheimer initiated coverage of CorMedix (NASDAQGM:CRMD) (DB:19KA) with a Outperform recommendation.
CorMedix Inc., headquartered in the United States, is a biopharmaceutical company mainly focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. A key project of CorMedix is Neutrolin, a novel anti-infective solution designed for the prevention of catheter-related bloodstream infections (CRBSIs) in patients on hemodialysis due to chronic kidney disease. Neutrolin, which has shown clinical effectiveness, combines an antimicrobial agent and an anticoagulant. This formulation not only aims to significantly reduce the incidence of dangerous infections but also ensures the functional longevity of central venous catheters, thereby addressing a critical medical need in a high-risk patient population.
Prior to this rating action, the stock closed at $7.78 on September 22, 2026, which is also the latest close price as of September 22, 2026. The stock experienced a price change of +0.26% over one week, compared to a baseline close of $7.76 on September 15, 2026. Over a one-month period, the stock saw a price change of -5.12% from a baseline close of $8.20 on August 21, 2026.
Separately from Oppenheimer's individual rating, aggregate analyst consensus data shows a current consensus target mean of $15.71 and a median of $15.30 as of September 15, 2026. This mean target represents an implied change of +101.90% from the baseline. The prior consensus target mean was also $15.71 as of August 28, 2026, representing a consensus target revision of 0.00%.
For the recommendation period of September 1, 2026, the aggregate analyst recommendations totaled 11, with 3 strong buy, 7 buy, 1 hold, 0 sell, and 0 strong sell ratings. This represents 90.9% positive recommendations and 9.1% hold recommendations. These figures are identical to the prior recommendation period of August 1, 2026, which also had 11 total recommendations with 3 strong buy, 7 buy, 1 hold, 0 sell, and 0 strong sell ratings.
In its latest earnings report on August 13, 2026, CorMedix reported an actual EPS of 0.29, compared to the estimated EPS of 0.2428, representing an EPS surprise of +19.44%. The company reported actual revenue of $101,931,000.00 against an estimate of $97,533,828.00. According to the company's Form EX-99.1 filing dated August 13, 2026, titled "CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE", CorMedix Therapeutics announced $101.9 million of total revenue and grant income for the second quarter of 2026, reflecting strong second quarter execution and positive underlying demand trends. The filing also reported a net income of $26.0 million and Adjusted EBITDA of $58.7 million for the quarter.
Recent analyst actions
| Date | Analyst | Prior | Latest recommendation | Action |
|---|---|---|---|---|
| September 23, 2026 | Oppenheimer | Outperform | initiated coverage |
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.